Daily Cardiology Research Analysis
Analyzed 228 papers and selected 3 impactful papers.
Summary
Analyzed 228 papers and selected 3 impactful articles.
Selected Articles
1. A closed-loop myocardial infarction theranostic platform activated by macrophage-derived nitric oxide and acidic microenvironment.
A platelet membrane–cloaked, NO-responsive NIR-II/FTY720 platform enabled NO-triggered imaging, ML-based quantification of macrophage activity, and acid-triggered immunomodulation in MI models, improving angiogenesis, cardiac function, and repair. It demonstrates a closed-loop, pathology-triggered theranostic strategy that adapts to dynamic inflammation.
Impact: Introduces a first-of-its-kind, closed-loop theranostic that couples sensing and therapy to endogenous inflammatory cues after MI, advancing precision immunomodulation in cardiology.
Clinical Implications: While preclinical, this platform suggests future noninvasive mapping of inflammatory burden and on-demand immunotherapy to optimize timing and dosing after MI. It could complement current imaging and guide individualized inflammation-resolution strategies.
Key Findings
- NO-activated NIR-II imaging specifically visualized inflammatory foci after MI and, via ML, yielded quantitative macrophage activity maps.
- Acid-triggered release of FTY720 reprogrammed macrophages toward a reparative phenotype and synergized with platelet-derived factors to promote angiogenesis.
- Closed-loop sensing-and-treatment improved cardiac repair and function in vivo, establishing a pathology-triggered theranostic paradigm.
Methodological Strengths
- Disease-relevant dual triggers (NO and acidity) with multimodal validation (imaging, ML quantification, functional outcomes).
- In vivo efficacy demonstrating improved cardiac repair alongside mechanistic macrophage reprogramming.
Limitations
- Preclinical (rodent) study; human safety, biodistribution, and immunogenicity remain untested.
- Manufacturing scalability, regulatory pathway, and performance in large-animal MI models require evaluation.
Future Directions: Scale to large-animal MI models, assess long-term safety/immunogenicity, integrate clinical NIR-II systems, and explore combination with guideline-directed medical therapy for inflammation resolution.
Precise management of the inflammatory response after myocardial infarction necessitates targeted engagement of cellular drivers. Here, we report a pathophysiology-guided theranostic platform that exploits two defining features of pro-inflammatory macrophages, their high-output nitric oxide (NO) production and localized acidic microenvironment, to enable concurrent sensing, quantification, and modulation of post-infarction inflammation. The platform, PM720@NRP, is engineered from platelet membranes encapsulating an NO-responsive NIR-II fluorophore and the immunomodulator FTY720. It delivers three integrated functions: (i) specific, NO-activated NIR-II imaging of inflammatory foci; (ii) machine learning-powered translation of imaging signals into quantitative maps of pro-inflammatory macrophage activity; (iii) acid-triggered release of FTY720 to reprogram macrophages toward a reparative phenotype, synergizing with platelet-derived factors to stimulate angiogenesis. This strategy provided real-time visualization and non-invasive quantification of inflammation, while improving cardiac function and repair. By repurposing pathological biomarkers as intrinsic triggers for diagnosis and treatment, this work establishes a closed-loop, biology-inspired paradigm that autonomously adapts to dynamic disease activity.
2. The optimal blood pressure target in old and very old patients with hypertension.
In a large target-trial emulation (n=132,430), a BP target below 130/80 mmHg was associated with lower cardiovascular events and all-cause mortality across ages 60–69, 70–79, and ≥80, without excess major adverse events. Benefits were consistent across subgroups, supporting lower targets even in very old adults.
Impact: Addresses a longstanding clinical uncertainty by leveraging real-world data, suggesting that intensive BP targets are beneficial and safe even ≥80 years.
Clinical Implications: Clinicians may consider a <130/80 mmHg target in older and very old hypertensive patients, integrating individual frailty, orthostatic risk, and medication tolerance, pending randomized trials.
Key Findings
- Across age groups 60–69, 70–79, and ≥80, a target <130/80 mmHg reduced composite CVD (HRs 0.91, 0.87, 0.77, respectively).
- All-cause mortality was also lower with the lower target in all age strata (HRs 0.89, 0.84, 0.80).
- No significant increase in major adverse events related to antihypertensive therapy was observed across age groups.
Methodological Strengths
- Large-scale target-trial emulation with robust subgroup analyses across age strata.
- Use of real-world EMR data capturing treatment adjustments and outcomes.
Limitations
- Observational emulation susceptible to residual confounding and treatment-selection bias.
- BP measurement frequency/accuracy and adherence may differ between groups.
Future Directions: Prospective randomized trials in very old adults; assessment of orthostatic hypotension, cognitive outcomes, frailty trajectories, and patient-reported outcomes under lower targets.
BACKGROUND: With the rise in older population globally, the optimal blood pressure (BP) target for antihypertensive therapy in those aged 60 and above remains to be evaluated in the real-world practice. This study evaluated the effectiveness and safety of standard versus lower BP targets in old (aged 60-79) and very old (aged ≥80) patients with hypertension in real-world clinical settings. METHODS: We emulated a target trial using electronic medical records from the Hong Kong Hospital Authority, including patients aged 60 years or above with a diagnosis of hypertension, uncontrolled BP and records of antihypertensives adjustments from 2008 to 2013. Patients were first categorized into 3 age groups (60-69, 70-79, ≥ 80) and then assigned to BP targets of either 130-140/80-90 mmHg or below 130/80 mmHg. Outcomes included major cardiovascular disease (CVD), end-stage renal disease, all-cause mortality and major adverse events related to antihypertensive treatment. RESULTS: Of 132 430 eligible patients identified, 52 553, 28 661 and 7106 patients aged 60-69, 70-79 and ≥ 80 years had BP targets of 130-140/80-90 mmHg, respectively; 11 148, 5636 and 1203 of patients in the same age groups had targets below 130/80 mmHg. Lower BP target was associated with reduced overall CVD and all-cause mortality: aged 60-69 years (CVD HR: 0.91 [95% CI, 0.85-0.96]; all-cause mortality: 0.89 [0.81-0.98]), aged 70-79 years (CVD: 0.87 [0.82-0.93]; all-cause mortality: 0.84 [0.78-0.91]), and aged≥80 years (CVD: 0.77 [0.69-0.86]; all-cause mortality: 0.80 [0.72-0.89]). No significant increase in major adverse events was observed in any age group. Results were consistent across all subgroups. CONCLUSION: Lowering BP of below 130/80 mmHg in old and very old patients was associated with better cardiovascular and mortality outcomes without increased adverse events. These findings suggest that a lower BP target may be beneficial and safe for older patients with hypertension.
3. Prognostic value of the baseline CAVIAR response score after cardiac resynchronization therapy: ten-year outcomes from the Markers and Response to CRT (MARC) study.
In a prospective CRT cohort with median 9-year follow-up, higher baseline CAVIAR tertiles were strongly associated with lower risks of cardiovascular hospitalization and all-cause mortality, independent of 6-month echocardiographic response. The score also related to ventricular tachyarrhythmia and MACE after adjusting for echo response, supporting its utility for long-term risk stratification.
Impact: Provides long-term, prospective evidence that a baseline composite CRT response score predicts hard outcomes, informing patient selection and follow-up strategies.
Clinical Implications: CAVIAR can augment pre-implant counseling, guide intensity of surveillance, and prioritize adjunctive therapies in lower-score patients at higher long-term risk after CRT.
Key Findings
- Higher baseline CAVIAR tertiles were associated with lower risk of CV hospitalization or all-cause death (baseline-adjusted HR 0.562).
- Associations with the primary endpoint and all-cause mortality persisted after adjusting for 6-month echocardiographic response (HR 0.599 and 0.524, respectively).
- CAVIAR was associated with ventricular tachyarrhythmia and MACE after adjustment for echo response (HR 0.576 and 0.600).
Methodological Strengths
- Prospective multicenter cohort with long-term follow-up (median 9 years)
- Multivariable and response-adjusted Cox models with clinically relevant endpoints
Limitations
- Observational design limits causal inference and residual confounding cannot be excluded
- CAVIAR score was calculable in 83% of the cohort, introducing potential selection bias
Future Directions: External validation across diverse CRT populations and integration into decision-support tools to refine candidacy and personalize follow-up intensity.
BACKGROUND: A substantial proportion of patients derive limited benefit from cardiac resynchronization therapy (CRT). The CRT-Age-QRS OBJECTIVE: To assess the association between baseline CAVIAR response score and long-term outcomes in the prospective Markers and Response to CRT (MARC) study. METHODS: Primary outcome was cardiovascular (CV) hospitalization or all-cause mortality. Secondary outcomes were all-cause mortality, ventricular tachyarrhythmia, and major adverse cardiac events (MACE: CV death, CV hospitalization, appropriate implantable cardioverter-defibrillator therapy). Outcomes were assessed with Kaplan-Meier and Cox models adjusted for clinical characteristics and 6-month echocardiographic response (left ventricle (LV) end-systolic volume reduction ≥15% and LV ejection fraction ≥35%). RESULTS: Of 240 MARC participants, 224 (93%) were included for long-term follow-up (median 9.0 years [interquartile range 4.7-11.6]) and the CAVIAR score was calculated in 185 (83%). The primary outcome occurred in 145 (65%) patients; 117 (52%) died; 62 (28%) experienced ventricular tachyarrhythmia; and 93 (42%) had MACE. Higher CAVIAR tertiles were associated with lower hazard ratio (HR) of the primary outcome and all-cause mortality in baseline-adjusted models (HR 0.562, p=0.001; HR 0.485, p<0.001, respectively) and after adjustment for echocardiographic response (HR 0.599, p<0.001; HR 0.524, p<0.001, respectively). CAVIAR was associated with ventricular tachyarrhythmia and MACE only after adjustment for echocardiographic response (HR 0.576, p=0.007; HR 0.600, p=0.003, respectively). CONCLUSION: A higher baseline CAVIAR response score predicted a lower risk of CV hospitalization and/or all-cause mortality after CRT.